Patent classifications
A61K31/336
USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
COMPOSITIONS COMPRISING CAROTENOIDS AND USE THEREOF
Microalgae extract and microalgae dried biomass compositions comprising carotenoids including but not limited to fucoxanthin and fatty acids, are provided.
COMPOSITIONS COMPRISING CAROTENOIDS AND USE THEREOF
Microalgae extract and microalgae dried biomass compositions comprising carotenoids including but not limited to fucoxanthin and fatty acids, are provided.
COMPOSITIONS COMPRISING CAROTENOIDS AND USE THEREOF
Microalgae extract and microalgae dried biomass compositions comprising carotenoids including but not limited to fucoxanthin and fatty acids, are provided.
DETERMINATION OF NFKB PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENES
A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of NFkB cellular signaling pathway target genes.
DETERMINATION OF NFKB PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENES
A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of NFkB cellular signaling pathway target genes.
PHARMACEUTICAL DOSAGE FORM OF COLESTIPOL
The present invention contemplates a high dose finished pharmaceutical dosage form comprising colestipol hydrochloride in its commercially available form (i.e., beads) without the need for further milling. A manufacturing process used to manufacture the instant high dose finished pharmaceutical dosage form comprising colestipol hydrochloride, which monitors moisture content throughout the granulation process, is also disclosed herein.
PHARMACEUTICAL DOSAGE FORM OF COLESTIPOL
The present invention contemplates a high dose finished pharmaceutical dosage form comprising colestipol hydrochloride in its commercially available form (i.e., beads) without the need for further milling. A manufacturing process used to manufacture the instant high dose finished pharmaceutical dosage form comprising colestipol hydrochloride, which monitors moisture content throughout the granulation process, is also disclosed herein.
METHODS AND COMPOSITIONS FOR TREATMENT OF HEAD LICE
The current invention relates to compositions and methods for treating head lice using compounds extracted from Cannabis sativa. The method can include a formulation including a compound extracted from cannabis and coconut oil.